| Products |
|
|
 |
| Contact Us |
 |
Address: 2766 Yingxiu Road, Jinan High-Tech Zone, China |
 |
Tel:
Sales: +86-531-88811783
Evaluation:+86-531-88806178
R&D: +86-531-88813691
Office: +86-531-88817621 |
 |
Fax: +86-531-88817925 |
 |
Zip Code: 250101 |
 |
Email:
Trade Department:
sales@trio-pharmatech.com
G&D&E:
register@trio-pharmatech.com
yzxpj@trio-pharmatech.com
R&D center::
newdrugs@trio-pharmatech.com |
|
|
|
| Cell Signaling Pathway Inhibitors |
Now Position:Home > Products > Cell Signaling Pathway Inhibitors < Inhibitors of EGFR pathways |
|
| Co-1686 Clovis(CAS:1374640-70-6) |
 |
|
|
Product No. |
|
TP1134A |
|
Name |
|
Co-1686 Clovis |
|
Synonyms |
|
Rociletinib N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide |
|
CAS Number |
|
1374640-70-6 |
|
Structure |
|
|
|
Brief Description |
|
CO-1686 is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively. Phase 2. |
|
Purity |
|
>99% |
|
Package |
|
5mg，10mg，20mg，50mg | |
|
|
|
|
|
